
    
      The maximum duration of the study period for a participant was approximatively 49 days broken
      down as follows:

        -  Screening period of up to 21 days;

        -  Influenza vaccination at Day 1;

        -  Follow-up period of 28 days (±2 days).

      MS treatment (Teriflunomide or interferon-β-1) was to be continued during the course of the
      study.
    
  